Trospium Chloride Tablet, Film Coated
Product Images NDC 72162-1108

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Trospium Chloride (NDC 72162-1108). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Image 01)

Chemical structure diagram of trospium chloride showing the molecular configuration with a quaternary ammonium group complexed with chlorine and other structural features including bicyclic rings and phenyl groups.*

FDA Label Image

Figure 1 (Image 02)

A line chart depicting plasma concentration (ng/mL) over time (hours post-dose) following administration. The graph shows a peak in plasma concentration shortly after dosing, followed by a gradual decline over a 48-hour period, with error bars representing variability at each time point.*

FDA Label Image

Figure 2 (Image 03)

A line graph depicting the mean change with standard error (SE) over week 1, week 4, and week 12 of treatment for two groups: placebo (N=256) and trospium chloride tablets (N=253). The trospium chloride group shows a more pronounced decrease compared to placebo, with p-values indicating statistical significance at weeks 4 and 12.*

FDA Label Image

Figure 3 (Image 04)

Line graph comparing mean change in a measured variable over 12 weeks between placebo (256 subjects) and Trospium Chloride tablets (253 subjects). The x-axis shows treatment duration in weeks (1, 4, 12) and the y-axis shows mean change in the variable with error bars. P-values for comparisons are noted at weeks 1, 4, and 12.*

FDA Label Image

Figure 4 (Image 05)

Line graph depicting mean change over weeks of treatment comparing Trospium Chloride tablets (solid line) and placebo (dashed line). The x-axis shows weeks of treatment (1, 4, 12), and the y-axis shows mean change with standard error. Trospium Chloride group shows greater reduction over time compared to placebo, with p-values indicated for statistical significance.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing mean changes over weeks 1, 4, and 12 of treatment between placebo and Trospium Chloride tablets. The y-axis shows mean change with standard error, and the x-axis represents the week of treatment. Trospium Chloride tablets show a greater mean reduction than placebo at all time points, with statistical significance (p<0.001) indicated.*

FDA Label Image

Label (Lbl721621108)

Label for Trospium Chloride Tablets 20 mg, film-coated oral tablets. The label shows the product is relabeled by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Perrigo. The package contains 60 tablets and includes storage instructions and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.